Filing Details
- Accession Number:
- 0001127602-19-030383
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-10-10 16:52:29
- Reporting Period:
- 2019-10-08
- Accepted Time:
- 2019-10-10 16:52:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
313143 | Haemonetics Corp | HAE | Surgical & Medical Instruments & Apparatus (3841) | 042882273 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1682069 | Mr. P. William Burke | 400 Wood Road Braintree MA 02184 | Evp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2019-10-08 | 18,950 | $122.34 | 35,718 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-10-09 | 2,900 | $122.72 | 32,818 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-10-09 | 8,356 | $123.61 | 24,462 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-10-09 | 11,448 | $124.59 | 13,014 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- This number includes unvested restricted stock units previously reported.
- Transaction pursuant to an existing 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.21 to $123.18, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.22 to $124.21, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.22 to $124.97, inclusive.